Congratulations to Heme T32 Scholar, Dr. Fahmin Basher for receiving a 3-year the Leukemia and Lymphoma Society Career Development Program Fellow Award! The title of her project is: “The Role of the DNA Sensor AIM2 in B Cell Fate and Function after HCT”

Congratulations to Dr Katherine Zhou who won both a 2024 Duke Cancer Institute Pilot award and the 2024 Young Investigator Award from ASCO.

Congratulations to T32 Fellow, Dr. Andrew Peseski for his recent publication, An epidemiologic study comparing cancer- and noncancer-associated venous thromboembolism in a racially diverse Southeastern United States county.

Click on the following link: PMID: 38817950

Congrats to Dr. Sainvil for receiving the 2023 Duke Cancer Institute Cancer Research Young Investigator Pilot Award RFA for a Community Outreach, Engagement and Equity award.  The title for the one year award is “Understanding Disparities in Biobanking Participation among Minoritized Patients Undergoing HSCT in Durham, NC”

Dr. Stefanie Sarantopoulos Named Division Chief of Hematologic Malignancies and Cellular Therapy

https://medicine.duke.edu/news/dr-stefanie-sarantopoulos-named-division-chief-hematologic-malignancies-and-cellular-therapy

Congrats to Dr. Fahmin Basher on her 2-year award from the American Society of Transplantation and Cellular Therapy for her project The Role of the DNA Sensor AIM2 in B Cell Fate and Function After HCT

Congratulations to current Hematology T32 Trainee, Dr. Hutton Chapman for receiving the Ralph G. Corey Legacy Award. This is a 2 year $25,000 award geared towards young investigators. (Please see link for more information about the award)

Heme T32 Fellow Joyce Hwang Receives 2023 Borden Scholars Award:

https://dhvi.duke.edu/blog/2023-borden-scholars-award-recipients

1/27/2023

1. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. PMID: 36613644

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820370/

2. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease: SYK Inhibition in Chronic GVHD. PMID: 36577483

https://pubmed.ncbi.nlm.nih.gov/36577483/

3. Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma. https://www.tandfonline.com/doi/full/10.1080/07357907.2022.2162073
4. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel Versus Umbilical Cord Blood. Transplantation and Cellular Therapy, 28 September 2022. PMID: 36179986 PMCID: PMC9825638

https://www.sciencedirect.com/science/article/abs/pii/S2666636722016554?via%3Dihub;

https://pubmed.ncbi.nlm.nih.gov/36179986/